 Primary endpoint of time to substantial symptom resolution was not met in acutely symptomatic, non-hospitalized COVID-19 patients CNM-ZnAg treatment was safe and well-tolerated SALT LAKE CITY, Dec. 27, 2022 GLOBE NEWSWIRE Clene Inc. Nasdaq: CLNN along with its subsidiaries, Clene and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company today announced ... The post Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg... 